Dublin, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
This Psoriatic Arthritis (PsA) - Epidemiology Forecast - 2032 report delivers an in-depth understanding of the historical and forecasted epidemiology of psoriatic arthritis (PsA) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Epidemiology
Psoriatic arthritis (PsA) epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted psoriatic arthritis (PsA) epidemiology segmented as the prevalent cases of psoriatic arthritis (PsA), diagnosed cases of psoriatic arthritis (PsA), gender-specific cases of psoriatic arthritis (PsA), age-specific cases of psoriatic arthritis (PsA) and severity-specific cases of psoriatic arthritis (PsA).
The report includes the prevalent psoriatic arthritis (PsA) scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country-wise psoriatic arthritis (PsA) Epidemiology
The epidemiology segment also provides psoriatic arthritis (PsA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 1.5 million in 2021.
As per the estimates, the US had the highest total patient population of psoriatic arthritis (PsA) in 2021. Among the EU5 countries, Spain had the highest total prevalent patient population of psoriatic arthritis (PsA), with more than 200,000 cases, followed by Italy in 2021. On the other hand, France had the lowest total prevalent patient population of psoriatic arthritis (PsA), close to 53,000 cases in 2021.
KOL Views
The publisher interviews KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential novel treatments by identifying the overall scenario of the indications.
Key Questions Answered
- What are the major factors that will drive the change in the patient population in psoriatic arthritis (PsA) during the forecast period (2019-2032)?
- What are the key findings pertaining to psoriatic arthritis (PsA) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of patients with psoriatic arthritis (PsA) across the 7MM during the forecast period (2019-2032)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
- What are the disease risk, burdens, and unmet needs of psoriatic arthritis (PsA)?
- What are the currently available treatments for psoriatic arthritis (PsA)?
Report Highlights
- 11-year forecast of psoriatic arthritis (PsA) epidemiology
- 7MM coverage
- Prevalent cases of psoriatic arthritis (PsA)
- Diagnosed cases of psoriatic arthritis (PsA)
- Age-specific cases of psoriatic arthritis (PsA)
- Gender-specific cases of psoriatic arthritis (PsA)
- Severity-specific cases of psoriatic arthritis (PsA)
Key Assessments
- Patient segmentation
- Disease risk and burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
3.1. Market Share (%) Distribution of PsA in 2019
3.2. Market Share (%) Distribution of PsA in 2032
4. Executive Summary of Psoriatic Arthritis
5. Disease Background and Overview
5.1. Introduction
5.2. Clinical Manifestations
5.3. Classification
5.4. Risk Factors
5.5. Pathogenesis
5.6. Diagnosis
5.7. Differential Diagnosis
5.8. Treatment and Management
5.8.1. ACR/NPF Recommendations for PsA
5.8.2. Summary of differences in recommendations
5.8.3. EULAR Recommendations
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Prevalence of PsA in the 7MM
6.3. Assumption and Rationale
6.4. The United States
6.4.1. Prevalent cases of PsA in the United States
6.4.2. Diagnosed Cases of PsA in the United States
6.4.3. Gender-specific Cases of PsA in the United States
6.4.4. Age-specific Cases of PsA in the United States
6.4.5. Severity-specific Cases of PsA in the United States
6.5. EU5
6.5.1. Total Prevalent Cases of PsA in the EU5
6.5.2. Germany
6.5.3. France
6.5.4. Italy
6.5.5. Spain
6.5.6. The United Kingdom
6.6. Japan
7. Patient Journey of Psoriatic Arthritis
8. SWOT Analysis
9. KOL Views
10. Unmet Needs
11. Market Access
12. Acronyms and Abbreviations
For more information about this report visit https://www.researchandmarkets.com/r/u3tklq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
